Mw. Frohlich et Ej. Small, STAGE-II NONSEMINOMATOUS TESTIS CANCER - THE ROLES OF PRIMARY AND ADJUVANT CHEMOTHERAPY, Urologic clinics of North America, 25(3), 1998, pp. 451
Historically, a retroperitoneal lymph node dissection (RPLND) has been
the primary treatment of stage II nonseminomatous germ cell tumor (NS
GCT) patients, whereas chemotherapy has been used in the adjuvant sett
ing. Increasing evidence of the efficacy of chemotherapy has led to ad
ditional treatment possibilities for stage II patients. Both chemother
apy and RPLND have a role in the primary therapy of stage II NSGCT, an
d both modalities can be used as secondary adjunctive therapy. Managem
ent of these patients now requires a renewed emphasis on risk stratifi
cation and on the integration of patient preferences into the manageme
nt algorithm.